⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

January 18, 2019Journal of Clinical OncologyOpen Access

Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report

View Full Paper

Ask AI

Bookmark

Share

Abstract

This expert consensus highlights the need for additional clinical trials to develop novel standard therapies for the treatment of ATL.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cook et al. (2019) studied this question.

synapsesocial.com/papers/69d8323f8c03fbaff8bedf5c https://doi.org/10.1200/jco.18.00501

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell LymphomaEarly-Phase Clinical Trial · 2010 · 354 citations
2Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphomaPrognostic Study · 2011 · 141 citations
3Point mutations inTP53but not inp15Ink4bandp16Ink4agenes represent poor prognosis factors in acute adult T cell leukemia/lymphomaPrognostic Study · 2015 · 4 citations
4Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002Prognostic Study · 2016 · 151 citations
5Adult T-Cell Leukemia/Lymphoma in Bahia, BrazilPrognostic Study · 2007 · 98 citations